Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

1 Jun 2022

Abstract excerpt

Abstract Background Epidermal growth factor receptor (EGFR) inhibitors, including cetuximab and panitumumab, are valuable therapeutics for colorectal cancer (CRC), but resistance to these inhibitors is common. The reason for such resistance is not well understood, which hampers development of better therapeutic strategies. Although activating mutations in KRAS, BRAF and PIK3CA are considered major drivers of CRC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35650607
DOI: 10.1186/s13046-022-02389-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancerPMID 35650607Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

HER2 activating mutations are targets for colorectal cancer treatment.Semantic proximity Read ↗

The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.Semantic proximity Read ↗

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cellsSemantic proximity Read ↗

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read ↗

ERBB2 deficiency enhances colorectal cancer progression through EGFR-dependent compensatory mechanismsSemantic proximity Read ↗

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSemantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.